2026 High Conviction - China Healthcare: High-Certainty Investment Opportunity Has Emerged
​Innovent's impressive growth trajectory is projected to continue, with product revenue expected to reach RMB20bn by 2027. Investors advised to...
549 Views
CHINA/HK: AI & RX - Together At Last !!
China's AI-driven drug discovery (AIDD) sector is growing rapidly, with leading drug and biotech companies entering R&D and drug-development...
112 Views
Innovent Biologics Inc (1801 HK): Dual Engine Growth Strategy Is Yielding Result
Innovent Biologics will be added to Hang Seng index after the market close on December 5. Last month, Innovent signed an $11B outsourcing deal with...
653 Views
China Healthcare Weekly Wrap (3-7 Aug)
Wuxi Apptec 2Q results beat; BeOne 2Q driven by robust Brukinsa; Innovent robust 2Q product revenue +13% QoQ; Alphamab licensed-out TROP2/HER3 ADC...
117 Views
China Healthcare Weekly (Oct.26) - Turning Point of Medical Device, Innovent-Takeda Deal Makes Sense
Companies cannot "defend" by just relying on limited products. The turning point of medical device has arrived. Innovent-Takeda deal makes sense,...
532 Views